皰疹性角膜炎（HK）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035）

市場概覽

• 預計到 2035 年，中國皰疹性角膜炎市場規模將從約 10.241 億美元大幅成長至 23.405 億美元。
• 市場成長受以下因素支撐：
• 擴大長期抗病毒抑制療法的使用範圍
• 對復發性和重症疾病的先進治療需求日益成長
• 市場規模的擴大是由疾病復發率上升、治療持續時間延長以及對可能導致視力喪失的併發症進行更有效的管理所推動的。
• 未來市場成長將取決於下一代抗病毒療法、角膜再生療法和復發預防策​​略的改進。

皰疹性角膜炎（HK）概述

皰疹性角膜炎（HK）是全球範圍內導致角膜失明的主要感染性疾病之一，主要由1型單純皰疹病毒（HSV-1）引起，HSV-2感染則較為罕見。初次感染後，病毒潛伏於三叉神經節內，病毒重新運作會導致進行性性角膜損傷和視力障礙。此病有多種臨床表現形式，包括上皮性角膜炎、基質性角膜炎、內皮炎和神經營養性角膜疾病，每種表現形式均與特定的病理機制和治療方法相關。

患者通常表現為單側眼痛、眼紅、畏光、流淚、視力下降和角膜感覺減退。反覆復發可導致慢性角膜瘢痕、角膜變薄、新生血管形成和視力喪失。診斷主要依據裂隙燈檢查和特徵性樹枝狀角膜潰瘍進行臨床判斷，但對於非典型或重症病例，PCR檢測可能有所幫助。

雖然局部抗病毒藥物（如更昔洛韋和阿昔洛韋）仍然是上皮性疾病的標準治療方法，但基質性角膜炎通常需要抗病毒藥物和皮質類固醇聯合治療，以抑制免疫介導的發炎。對於復發率高的患者，廣泛使用口服抗病毒藥物（如阿昔洛韋或伐昔洛韋）進行預防性治療，以降低復發風險。儘管已有多種治療方法，但復發性性行為感染和免疫介導的角膜疾病仍然是尚未解決的重大臨床挑戰。治療方向正日益著重於改善抗病毒策略、神經營養療法以及旨在維持視力的長期復發預防方法。

主要亮點

• 預計到 2025 年，中國皰疹性角膜炎新病例數將增加到 2035 年的近 221,717 例，反映出該疾病負擔日益加重。
• HSV病毒重新運作仍然是導致進行性性角膜損傷和視力障礙的主要原因。
• 角膜基質狹窄性角膜炎和神經營養性角膜病變仍是長期視力障礙的主要原因。
• 長期抗病毒預防治療在降低復發頻率和延緩疾病進展方面起著至關重要的作用。
• 人們對這種疾病的認知不斷提高，早期診斷得以實現，眼科治療也得到了改進，從而提高了疾病的治療效果。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期管道

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求及其未來透過新興治療方法實現的可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Herpetic Keratitis (HK) Market Outlook

Thelansis's "Herpetic Keratitis (HK) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Herpetic Keratitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Herpetic Keratitis (HK) Overview

Herpetic keratitis (HK) is a major infectious cause of corneal blindness worldwide, primarily caused by herpes simplex virus type 1 (HSV-1) and less commonly HSV-2. Following primary infection, the virus establishes latency within the trigeminal ganglion, with recurrent viral reactivation leading to progressive corneal injury and visual impairment. The disease encompasses multiple clinical forms, including epithelial keratitis, stromal keratitis, endotheliitis, and neurotrophic keratopathy, each associated with distinct pathological mechanisms and treatment approaches.

Patients commonly present with unilateral eye pain, redness, photophobia, tearing, blurred vision, and reduced corneal sensation. Recurrent disease can result in chronic corneal scarring, thinning, neovascularization, and vision loss. Diagnosis is primarily clinical through slit-lamp examination and characteristic dendritic corneal ulcers, while PCR testing may support diagnosis in atypical or severe cases.

Topical antivirals such as ganciclovir and acyclovir remain the standard treatment for epithelial disease, whereas stromal keratitis typically requires combined antiviral therapy and corticosteroids to control immune-mediated inflammation. Oral antiviral prophylaxis with acyclovir or valacyclovir is widely used to reduce recurrence risk in patients with frequent relapses. Despite available therapies, recurrent infection and immune-mediated corneal damage continue to represent significant unmet clinical challenges. The evolving treatment landscape is increasingly focused on improved antiviral strategies, neurotrophic therapies, and long-term recurrence prevention approaches aimed at preserving visual function.

Key Highlights

• In China, incident cases of herpetic keratitis are projected to increase from approximately 206,184 in 2025 to nearly 221,717 by 2035, reflecting a growing disease burden.
• Recurrent HSV reactivation remains the primary driver of progressive corneal damage and vision impairment.
• Stromal keratitis and neurotrophic keratopathy continue to represent major causes of long-term visual morbidity.
• Long-term antiviral prophylaxis plays a critical role in reducing recurrence frequency and disease progression.
• Increasing awareness, earlier diagnosis, and improved ophthalmic management are supporting better disease outcomes.

Market Overview

• The China herpetic keratitis market is projected to grow from approximately $1,024.10 MN to $2,340.50 MN by 2035, reflecting substantial market expansion.
• Market growth is supported by:
• Increasing adoption of long-term antiviral suppression therapies
• Growing demand for advanced ophthalmic treatments for recurrent and severe disease
• Market value growth is driven by rising disease recurrence, prolonged treatment duration, and increased management of vision-threatening complications.
• Future market growth will depend on next-generation antiviral therapies, regenerative corneal treatments, and improved recurrence prevention strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)